Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö, C Balotta, E Boeri, ... The Journal of infectious diseases 192 (6), 958-966, 2005 | 559 | 2005 |
Beyond sparsity: Tree regularization of deep models for interpretability M Wu, M Hughes, S Parbhoo, M Zazzi, V Roth, F Doshi-Velez Proceedings of the AAAI conference on artificial intelligence 32 (1), 2018 | 319 | 2018 |
European guidelines on the clinical management of HIV-1 tropism testing LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vézinet, B Clotet, ... The Lancet infectious diseases 11 (5), 394-407, 2011 | 316 | 2011 |
Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ... Clinical infectious diseases 62 (5), 655-663, 2016 | 191 | 2016 |
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach D Paraskevis, O Pybus, G Magiorkinis, A Hatzakis, AMJ Wensing, ... Retrovirology 6, 1-11, 2009 | 154 | 2009 |
A novel methodology for large-scale phylogeny partition MCF Prosperi, M Ciccozzi, I Fanti, F Saladini, M Pecorari, V Borghi, ... Nature communications 2 (1), 321, 2011 | 141 | 2011 |
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes DA Van De Vijver, AMJ Wensing, G Angarano, B Åsjö, C Balotta, E Boeri, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 41 (3), 352-360, 2006 | 137 | 2006 |
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples G Venturi, M Catucci, L Romano, P Corsi, F Leoncini, PE Valensin, ... The Journal of infectious diseases 181 (2), 740-745, 2000 | 130 | 2000 |
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19 I Vicenti, M Zazzi, F Saladini Expert Opinion on Therapeutic Patents 31 (4), 325-337, 2021 | 128 | 2021 |
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents A Brai, R Fazi, C Tintori, C Zamperini, F Bugli, M Sanguinetti, E Stigliano, ... Proceedings of the National Academy of Sciences 113 (19), 5388-5393, 2016 | 119 | 2016 |
The development of artificial neural networks to predict virological response to combination HIV therapy B Larder, D Wang, A Revell, J Montaner, R Harrigan, F De Wolf, J Lange, ... Antiviral therapy 12 (1), 15-24, 2007 | 97 | 2007 |
Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens A Marconi, M Balestrieri, G Comastri, FR Pulvirenti, W Gennari, ... Clinical microbiology and infection 15 (1), 93-97, 2009 | 93 | 2009 |
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe A De Luca, D Dunn, M Zazzi, R Camacho, C Torti, I Fanti, R Kaiser, ... The Journal of infectious diseases 207 (8), 1216-1220, 2013 | 92 | 2013 |
Clinically validated genotype analysis: guiding principles and statistical concerns F Brun-Vezinet, D Costagliola, MA Khaled, V Calvez, F Clavel, B Clotet, ... Antiviral therapy 9 (4), 465-478, 2004 | 89 | 2004 |
New findings in HCV genotype distribution in selected West European, Russian and Israeli regions V Kartashev, M Döring, L Nieto, E Coletta, R Kaiser, S Sierra, A Guerrero, ... Journal of Clinical Virology 81, 82-89, 2016 | 88 | 2016 |
Combining kernel and model based learning for HIV therapy selection S Parbhoo, J Bogojeska, M Zazzi, V Roth, F Doshi-Velez AMIA Summits on Translational Science Proceedings 2017, 239, 2017 | 87 | 2017 |
Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge F Picarazzi, I Vicenti, F Saladini, M Zazzi, M Mori Molecules 25 (23), 5695, 2020 | 86 | 2020 |
Selecting anti-HIV therapies based on a variety of genomic and clinical factors M Rosen-Zvi, A Altmann, M Prosperi, E Aharoni, H Neuvirth, ... Bioinformatics 24 (13), i399-i406, 2008 | 85 | 2008 |
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time D Frentz, CAB Boucher, M Assel, A De Luca, M Fabbiani, F Incardona, ... PloS one 5 (7), e11505, 2010 | 84 | 2010 |
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with
R Gagliardini, A Ciccullo, A Borghetti, F Maggiolo, D Bartolozzi, V Borghi, ... Open forum infectious diseases 5 (6), ofy113, 2018 | 80 | 2018 |